Summary
McKesson Corporation reported a 5% increase in revenue for the first quarter of fiscal year 2017, reaching $49.7 billion, compared to $47.5 billion in the prior year. This growth was primarily driven by the Distribution Solutions segment, bolstered by recent acquisitions and market expansion. While revenue saw a healthy increase, net income attributable to McKesson Corporation decreased by 6% to $542 million ($2.38 per diluted share) from $576 million ($2.45 per diluted share) in the same period last year. This decline was largely due to a significant $113 million after-tax loss from the divestiture of its Brazilian pharmaceutical distribution business. The company announced a significant strategic move: a joint venture with Change Healthcare Holdings, Inc., which will combine a majority of McKesson's Technology Solutions (MTS) business with Change Healthcare's assets. This move is expected to create a new healthcare information technology company, with McKesson retaining a 70% ownership stake. The transaction is anticipated to close in the first half of calendar year 2017, subject to regulatory approvals. This strategic partnership is a key development for McKesson's future growth and focus in the healthcare technology sector.
Financial Highlights
50 data points| Revenue | $49.73B |
| Cost of Revenue | $46.83B |
| Gross Profit | $2.91B |
| Operating Expenses | $1.94B |
| Operating Income | $972.00M |
| Net Income | $542.00M |
| EPS (Basic) | $2.41 |
| EPS (Diluted) | $2.38 |
| Shares Outstanding (Basic) | 225.00M |
| Shares Outstanding (Diluted) | 228.00M |
Key Highlights
- 1Revenue increased by 5% to $49.7 billion in Q1 FY17, primarily driven by the Distribution Solutions segment.
- 2Net income attributable to McKesson Corporation decreased by 6% to $542 million ($2.38/share) due to a loss from discontinued operations.
- 3Announced a joint venture with Change Healthcare, contributing the majority of McKesson's Technology Solutions business, retaining a 70% stake.
- 4Acquired Vantage Oncology Holdings LLC and Biologics, Inc. in April 2016 to enhance specialty pharmaceutical distribution and oncology offerings.
- 5Acquired UDG Healthcare Plc's pharmaceutical distribution businesses in Ireland and the UK to expand international presence.
- 6Operating expenses saw a slight increase due to acquisitions, partially offset by cost savings from a restructuring plan.
- 7The company maintained a debt-to-capital ratio of 42.5% as of June 30, 2016, indicating a solid financial position.